GlassScriptPhysician profile
Annette Caravia
NPI 1346644234
$8,674.61
in general payments reported to CMS, 2019-2025
32 companies · $2,586 in 2025
The $2,586 reported for 2025 was more than what 98% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $1,547 · 2023: $1,298 · 2024: $2,262 · 2025: $2,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,659 · Education: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,658.99 |
| Education | $487.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.85 | 2022-2025 | |
| Janssen Biotech, INC. | $941.15 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Incyte Corporation | $893.32 | 2021-2025 | Niktimvo, Jakafi, Monjuvi |
| Astellas Pharma US INC | $742.89 | 2021-2025 | Cresemba, Xospata |
| Jazz Pharmaceuticals INC. | $671.97 | 2021-2025 | |
| Amgen INC. | $617.09 | 2021-2025 | Blincyto, Blincyto, Kyprolis |
| Genentech USA, INC. | $557.25 | 2022-2025 | Columvi, Venclexta, Polivy |
| Pfizer INC. | $507.43 | 2022-2025 | |
| Btg International INC. | $335.78 | 2022-2025 | Voraxaze |
| Stemline Therapeutics INC. | $300.32 | 2022-2025 | Elzonris |
| Beigene USA, INC. | $250.00 | 2021-2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $228.53 | 2021-2024 | |
| Syndax Pharmaceuticals, INC. | $189.18 | 2025 | Revuforj |
| Legend Biotech USA INC. | $139.65 | 2024 | Carvykti |
| Gamida Cell INC. | $125.00 | 2025 | Omisirge |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $125.00 | 2023 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2025 | |
| Kite Pharma, INC. | $123.88 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.50 | 2025 | Abecma |
| Genmab U.S., INC. | $121.87 | 2024 | Epkinly |
| Kyowa Kirin, INC. | $120.96 | 2021 | |
| Eisai INC. | $114.50 | 2021 | |
| Celgene Corporation | $95.36 | 2022 | |
| Stryker Corporation | $40.36 | 2023 | |
| Fresenius Kabi USA, LLC | $35.51 | 2025 | Ivenix Infusion System |
| Janssen Scientific Affairs, LLC | $27.78 | 2023 | Darzalex |
| Sanofi-Aventis U.S. LLC | $26.23 | 2025 | |
| Genzyme Corporation | $22.17 | 2024 | |
| Adc Therapeutics America, INC. | $21.18 | 2025 | |
| Geron Corporation | $21.08 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $16.28 | 2025 | Lynozyfic |
| Novartis Pharmaceuticals Corporation | $14.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Caravia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.